EXEL vs. VRTX
Compare and contrast key facts about Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EXEL or VRTX.
Correlation
The correlation between EXEL and VRTX is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
EXEL vs. VRTX - Performance Comparison
Loading data...
Key characteristics
EXEL:
1.91
VRTX:
0.05
EXEL:
2.65
VRTX:
0.34
EXEL:
1.37
VRTX:
1.05
EXEL:
1.08
VRTX:
0.15
EXEL:
12.23
VRTX:
0.41
EXEL:
5.18%
VRTX:
8.81%
EXEL:
34.96%
VRTX:
28.17%
EXEL:
-97.38%
VRTX:
-91.77%
EXEL:
-26.56%
VRTX:
-17.76%
Fundamentals
EXEL:
$10.06B
VRTX:
$109.14B
EXEL:
$1.76
VRTX:
-$3.83
EXEL:
2.27
VRTX:
1.19
EXEL:
4.60
VRTX:
9.94
EXEL:
4.52
VRTX:
6.77
EXEL:
$1.74B
VRTX:
$11.09B
EXEL:
$1.69B
VRTX:
$9.54B
EXEL:
$650.08M
VRTX:
-$228.00M
Returns By Period
In the year-to-date period, EXEL achieves a 8.62% return, which is significantly higher than VRTX's 5.54% return. Over the past 10 years, EXEL has outperformed VRTX with an annualized return of 25.86%, while VRTX has yielded a comparatively lower 13.01% annualized return.
EXEL
8.62%
4.96%
-0.22%
69.26%
5.71%
25.86%
VRTX
5.54%
-10.62%
-17.76%
0.52%
8.33%
13.01%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EXEL vs. VRTX — Risk-Adjusted Performance Rank
EXEL
VRTX
EXEL vs. VRTX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
EXEL vs. VRTX - Dividend Comparison
Neither EXEL nor VRTX has paid dividends to shareholders.
Drawdowns
EXEL vs. VRTX - Drawdown Comparison
The maximum EXEL drawdown since its inception was -97.38%, which is greater than VRTX's maximum drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for EXEL and VRTX. For additional features, visit the drawdowns tool.
Loading data...
Volatility
EXEL vs. VRTX - Volatility Comparison
The current volatility for Exelixis, Inc. (EXEL) is 10.57%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 13.00%. This indicates that EXEL experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
EXEL vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Exelixis, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EXEL vs. VRTX - Profitability Comparison
EXEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Exelixis, Inc. reported a gross profit of 546.79M and revenue of 566.76M. Therefore, the gross margin over that period was 96.5%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.41B and revenue of 2.77B. Therefore, the gross margin over that period was 86.9%.
EXEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Exelixis, Inc. reported an operating income of 163.21M and revenue of 566.76M, resulting in an operating margin of 28.8%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported an operating income of 630.10M and revenue of 2.77B, resulting in an operating margin of 22.8%.
EXEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Exelixis, Inc. reported a net income of 139.86M and revenue of 566.76M, resulting in a net margin of 24.7%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a net income of 646.30M and revenue of 2.77B, resulting in a net margin of 23.3%.